Development
Development of ASTROMELANIN
Our work with astromelanin began in 2020.
December 2020
Primary spectral study of melanin.
February 2021
Study of samples using Electron Paramagnetic Resonance, which directly reflects their antioxidant properties.
March 2021
A strain of Antarctic yeast Nadsoniella nigra var. hesuelica was obtained from the yeast culture storage base and practical work on growing raw materials for production began.
June 2021
Conditions for maintaining the best reproduction and accumulation of melanin in the strain on a solid nutrient medium were selected. In addition, strain dilution in a liquid medium on various aqueous substrates was tested.
The optimal substrate for rapid and stable growth of the strain was found. Strain cells were isolated from aqueous substrates and prepared for melanin extraction.
July 2021
Cultivation of two different strains under normal conditions was launched. Methods for separating the strain from the cultivation medium have been selected.
October 2021
We independently isolated the first batch of melanin from our own raw material of black yeast Nadsoniella Nigra
We selected the necessary parameters for isolating melanin from the finished yeast mass, which we grew for 3 months.
An EMR study was conducted to determine the antioxidant activity of different forms of melanin.
Our sample showed the highest antioxidant activity, which is comparable with the data from the works of Lyakh S. P.
A comparative study was conducted of available melanins and those isolated from the Nadsoniella Nigra strain (VKM F-2137) using the original method using the EPR (electron paramagnetic resonance) method.
November 2021
A technology for obtaining a water-soluble form of melanin has been developed.
Tests were carried out with another form of melanin obtained from a yeast structure.
Studies were conducted on the antioxidant activity of melanin samples isolated in various ways, using the Electron Paramagnetic Resonance (EPR) method.
June 2022
The technology for isolating melanin from raw materials has been improved. The output is 150% more finished substance from the same volume of raw materials, which reduces production costs.
The drug opens up a fundamentally new direction in the treatment of cancer.
In addition, there is data on its positive use in the treatment of type 2 diabetes, bronchial asthma and stomach ulcers, it has a clearly expressed immunomodulatory effect,
The most difficult stage is formula development.
This is associated with the highest risks, since there are a huge number of methods for isolating, processing, drying and other procedures at each stage and this entire chain must be done correctly, since if something does not work out, you need to look for the cause at each of the stages passed and start all over again. And we have already passed this most difficult stage of development. Our drug was named Alginar
Development of manufacturing technology "Alginar"
November 2022
Тoxicity studies open
December 2022
Alginar business plan open
Janiary 2023
Alginar's first round of funding
March 2023
The first batch of Alginar capsules has been produced open
September 2023
Preparation for industrial production Alginar open
Oсtober 2023
New melanin converter for research open
November 2023
In Vitro test results Alginar open
Febriary 2024
Clinical studies alginar open
March 2024
Interim report on the use of Alginar open
October 2024
Second report on the Alginar research